List of bibliographic references
Number of relevant bibliographic references: 9.
| Ident. | Authors (with country if any) | Title |
|---|
| 000088 (2017) |
Robert L. Coleman [États-Unis] ; Amit M. Oza [Canada] ; Domenica Lorusso [Italie] ; Carol Aghajanian [États-Unis] ; Ana Oaknin [Espagne] ; Andrew Dean [Australie] ; Nicoletta Colombo [Italie] ; Johanne I. Weberpals [Canada] ; Andrew Clamp [Royaume-Uni] ; Giovanni Scambia [Italie] ; Alexandra Leary [France] ; Robert W. Holloway [États-Unis] ; Margarita Amenedo Gancedo [Espagne] ; Peter C. Fong [Nouvelle-Zélande] ; Jeffrey C. Goh [Australie] ; David M. O'Malley [États-Unis] ; Deborah K. Armstrong [États-Unis] ; Jesus Garcia-Donas [Espagne] ; Elizabeth M. Swisher [États-Unis] ; Anne Floquet [France] ; Gottfried E. Konecny [États-Unis] ; Iain A. Mcneish [Royaume-Uni] ; Clare L. Scott [Australie] ; Terri Cameron [États-Unis] ; Lara Maloney [États-Unis] ; Jeff Isaacson [États-Unis] ; Sandra Goble [États-Unis] ; Caroline Grace [États-Unis] ; Thomas C. Harding [États-Unis] ; Mitch Raponi [États-Unis] ; James Sun [États-Unis] ; Kevin K. Lin [États-Unis] ; Heidi Giordano [États-Unis] ; Jonathan A. Ledermann [Royaume-Uni] | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. |
| 000089 (2017) |
Elizabeth M. Swisher [États-Unis] ; Kevin K. Lin [États-Unis] ; Amit M. Oza [Canada] ; Clare L. Scott [Australie] ; Heidi Giordano [États-Unis] ; James Sun [États-Unis] ; Gottfried E. Konecny [États-Unis] ; Robert L. Coleman [États-Unis] ; Anna V. Tinker [Canada] ; David M. O'Malley [États-Unis] ; Rebecca S. Kristeleit [Royaume-Uni] ; Ling Ma [États-Unis] ; Katherine M. Bell-Mcguinn [États-Unis] ; James D. Brenton [Royaume-Uni] ; Janiel M. Cragun [États-Unis] ; Ana Oaknin [Espagne] ; Isabelle Ray-Coquard [France] ; Maria I. Harrell [États-Unis] ; Elaina Mann [États-Unis] ; Scott H. Kaufmann [États-Unis] ; Anne Floquet [France] ; Alexandra Leary [France] ; Thomas C. Harding [États-Unis] ; Sandra Goble [États-Unis] ; Lara Maloney [États-Unis] ; Jeff Isaacson [États-Unis] ; Andrew R. Allen [États-Unis] ; Lindsey Rolfe [États-Unis] ; Roman Yelensky [États-Unis] ; Mitch Raponi [États-Unis] ; Iain A. Mcneish [Royaume-Uni] | Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. |
| 000097 (2017) |
Michelle K. Wilson [Canada] ; Michael L. Friedlander ; Stephanie Lheureux ; William Small ; Andrés Poveda ; Eric Pujade-Lauraine ; Katherine Karakasis ; Monica Bacon ; Valerie Bowering ; Tanya Chawla ; Amit M. Oza | Resisting RECIST-Uniformity Versus Clinical Validity. |
| 000154 (2017) |
Eric Pujade-Lauraine [France] ; Jonathan A. Ledermann [Royaume-Uni] ; Frédéric Selle [France] ; Val Gebski [Australie] ; Richard T. Penson [États-Unis] ; Amit M. Oza [Canada] ; Jacob Korach [Israël] ; Tomasz Huzarski [Pologne] ; Andrés Poveda [Espagne] ; Sandro Pignata [Italie] ; Michael Friedlander [Australie] ; Nicoletta Colombo [Italie] ; Philipp Harter [Allemagne] ; Keiichi Fujiwara [Japon] ; Isabelle Ray-Coquard [France] ; Susana Banerjee [Royaume-Uni] ; Joyce Liu [États-Unis] ; Elizabeth S. Lowe [États-Unis] ; Ralph Bloomfield [Royaume-Uni] ; Patricia Pautier [France] | Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. |
| 000425 (2017) |
Michelle K. Wilson [Nouvelle-Zélande] ; Michael L. Friedlander [Australie] ; Florence Joly [France] ; Amit M. Oza [Canada] | A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve. |
| 000686 (2016) |
Bradley J. Monk [États-Unis] ; Andrés Poveda [Espagne] ; Ignace Vergote [Belgique] ; Francesco Raspagliesi [Italie] ; Keiichi Fujiwara [Japon] ; Duk-Soo Bae [Corée du Sud] ; Ana Oaknin [Espagne] ; Isabelle Ray-Coquard [France] ; Diane M. Provencher [Canada] ; Beth Y. Karlan [États-Unis] ; Catherine Lhommé [France] ; Gary Richardson [Australie] ; Dolores Gallardo Rinc N [Mexique] ; Robert L. Coleman [États-Unis] ; Christian Marth [Autriche] ; Arija Brize [Lettonie] ; Michel Fabbro [France] ; Andrés Redondo [Espagne] ; Aristotelis Bamias [Grèce] ; Haijun Ma [États-Unis] ; Florian D. Vogl [États-Unis] ; Bruce A. Bach [États-Unis] ; Amit M. Oza [Canada] | Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. |
| 000837 (2015) |
Amit M. Oza [Canada] ; Adrian D. Cook [Royaume-Uni] ; Jacobus Pfisterer [Allemagne] ; Andrew Embleton [Royaume-Uni] ; Jonathan A. Ledermann [Royaume-Uni] ; Eric Pujade-Lauraine [France] ; Gunnar Kristensen [Norvège] ; Mark S. Carey [Canada] ; Philip Beale [Australie] ; Andrés Cervantes [Espagne] ; Tjoung-Won Park-Simon [Allemagne] ; Gordon Rustin [Royaume-Uni] ; Florence Joly [France] ; Mansoor R. Mirza [Danemark] ; Marie Plante [Canada] ; Michael Quinn [Australie] ; Andrés Poveda [Espagne] ; Gordon C. Jayson [Royaume-Uni] ; Dan Stark [Royaume-Uni] ; Ann Marie Swart [Royaume-Uni] ; Laura Farrelly [Royaume-Uni] ; Richard Kaplan [Royaume-Uni] ; Mahesh K B. Parmar [Royaume-Uni] ; Timothy J. Perren [Royaume-Uni] | Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial |
| 000C12 (2014) |
Bradley J. Monk [États-Unis] ; Andrés Poveda [Espagne] ; Ignace Vergote [Belgique] ; Francesco Raspagliesi [Italie] ; Keiichi Fujiwara [Japon] ; Duk-Soo Bae [Corée du Sud] ; Ana Oaknin [Espagne] ; Isabelle Ray-Coquard [France] ; Diane M. Provencher [Canada] ; Beth Y. Karlan [États-Unis] ; Catherine Lhommé [France] ; Gary Richardson [Australie] ; Dolores Gallardo Rinc N [Mexique] ; Robert L. Coleman [États-Unis] ; Thomas J. Herzog [États-Unis] ; Christian Marth [Autriche] ; Arija Brize [Lettonie] ; Michel Fabbro [France] ; Andrés Redondo [Espagne] ; Aristotelis Bamias [Grèce] ; Marjan Tassoudji [Royaume-Uni] ; Lynn Navale [États-Unis] ; Douglas J. Warner [États-Unis] ; Amit M. Oza [Canada] | Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. |
| 001417 (2011) |
Timothy J. Perren [Royaume-Uni] ; Ann Marie Swart [États-Unis] ; Jacobus Pfisterer [Allemagne] ; Jonathan A. Ledermann [Royaume-Uni] ; Eric Pujade-Lauraine [France] ; Gunnar Kristensen [Norvège] ; Mark S. Carey [Canada] ; Philip Beale [Australie] ; Andres Cervantes ; Christian Kurzeder [Allemagne] ; Andreas Du Bois [Allemagne] ; Jalid Sehouli ; Rainer Kimmig [Allemagne] ; Anne St Hle [Allemagne] ; Fiona Collinson [Royaume-Uni] ; Sharadah Essapen [Royaume-Uni] ; Charlie Gourley ; Alain Lortholary ; Frédéric Selle ; Mansoor R. Mirza ; Arto Leminen ; Marie Plante [Canada] ; Dan Stark [Royaume-Uni] ; WENDI QIAN [Royaume-Uni, États-Unis] ; Mahesh K. B. Parmar [États-Unis] ; Amit M. Oza | A Phase 3 Trial of Bevacizumab in Ovarian Cancer |
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 5 | Female |
| 5 | Humans |
| 5 | Ovarian Neoplasms (drug therapy) |
| 4 | Middle Aged |
| 3 | Aged |
| 3 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 3 | Disease-Free Survival |
| 3 | Double-Blind Method |
| 3 | Neoplasm Recurrence, Local (drug therapy) |
| 3 | Ovarian Neoplasms (pathology) |
| 3 | Paclitaxel (administration & dosage) |
| 2 | Bevacizumab |
| 2 | Neoplasm Staging |
| 2 | Neoplasms, Glandular and Epithelial (drug therapy) |
| 2 | Ovarian Neoplasms (genetics) |
| 2 | Ovarian Neoplasms (mortality) |
| 2 | Recombinant Fusion Proteins (administration & dosage) |
| 2 | Recombinant Fusion Proteins (adverse effects) |
| 1 | Adult |
| 1 | Aged, 80 and over |
| 1 | Angiogenesis Inhibitors (administration & dosage) |
| 1 | Angiogenesis Inhibitors (adverse effects) |
| 1 | Angiopoietin-1 (antagonists & inhibitors) |
| 1 | Angiopoietin-2 (antagonists & inhibitors) |
| 1 | Antiangiogenic agent |
| 1 | Antibodies, Monoclonal, Humanized (administration & dosage) |
| 1 | Antineoplastic Agents (pharmacology) |
| 1 | Antineoplastic Agents (therapeutic use) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (adverse effects) |
| 1 | Antineoplastic agent |
| 1 | Ascites (etiology) |
| 1 | Australia |
| 1 | BRCA1 Protein (genetics) |
| 1 | BRCA2 Protein (genetics) |
| 1 | Canada |
| 1 | Carboplatin (administration & dosage) |
| 1 | Disease Progression |
| 1 | Drug Administration Schedule |
| 1 | Drug Resistance, Neoplasm (drug effects) |
| 1 | Edema (chemically induced) |
| 1 | Europe |
| 1 | Fallopian Tube Neoplasms (drug therapy) |
| 1 | Fallopian Tube Neoplasms (genetics) |
| 1 | Fallopian Tube Neoplasms (pathology) |
| 1 | Follow-Up Studies |
| 1 | Genes, BRCA1 |
| 1 | Genes, BRCA2 |
| 1 | Germ-Line Mutation (genetics) |
| 1 | Immunomodulator |
| 1 | Indoles (therapeutic use) |
| 1 | Infusions, Intravenous |
| 1 | Intention to Treat Analysis |
| 1 | International Agencies |
| 1 | Maintenance Chemotherapy |
| 1 | Malignant tumor |
| 1 | Medicine |
| 1 | Mutation |
| 1 | Neoplasm Grading |
| 1 | Neoplasm Recurrence, Local (genetics) |
| 1 | Neoplasm Recurrence, Local (mortality) |
| 1 | Neoplasm Recurrence, Local (pathology) |
| 1 | Neoplasms, Glandular and Epithelial (genetics) |
| 1 | Neoplasms, Glandular and Epithelial (pathology) |
| 1 | New Zealand |
| 1 | Ovarian Neoplasms (complications) |
| 1 | Ovary cancer |
| 1 | Paclitaxel (adverse effects) |
| 1 | Peritoneal Neoplasms (drug therapy) |
| 1 | Peritoneal Neoplasms (genetics) |
| 1 | Peritoneal Neoplasms (pathology) |
| 1 | Phase III trial |
| 1 | Phthalazines (therapeutic use) |
| 1 | Piperazines (therapeutic use) |
| 1 | Platinum (pharmacology) |
| 1 | Poly(ADP-ribose) Polymerase Inhibitors (therapeutic use) |
| 1 | Poly(ADP-ribose) Polymerases (chemistry) |
| 1 | Prognosis |
| 1 | Prospective Studies |
| 1 | Salvage Therapy |
| 1 | Survival Analysis |
| 1 | Survival Rate |
| 1 | Tablets |
| 1 | Time Factors |
| 1 | Treatment Outcome |
| 1 | Vascular endothelium growth factor |
| 1 | Withholding Treatment |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Canada/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i -k "Amit M. Oza"
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i \
-Sk "Amit M. Oza" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Canada
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Amit M. Oza
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
